Please login to the form below

Not currently logged in


This page shows the latest Extavia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

to Novartis’ Extavia which had been the only recommended drug after a first cost appraisal.

Latest news

  • Novartis’ Extavia evades NICE restrictions on MS drugs Novartis’ Extavia evades NICE restrictions on MS drugs

    Multiple sclerosis patients in England and Wales look set to have just one interferon therapy option after draft NICE guidance backed routine funding for Novartis’ Extavia and rejected other drugs. ... The MS Society said the proposals won’t affect

  • Biogen Idec sues for patent infringement

    Rebif generated global sales of $2.1bn in 2009, and Extavia achieved $20m in the first quarter. ... Novartis received approval last year to sell Extavia and currently pays royalties to Bayer.

  • FDA approves Extavia for MS

    Extavia received EU approval in May 2008 to treat early and relapsing forms of MS. ... Extavia is reportedly the "first in a new planned portfolio" of MS medicines for Novartis.

  • Novartis gets MS drug approval

    Novartis has announced that the European Commission has granted approval for its new multiple sclerosis (MS) treatment, Extavia, and has said it intends to continue broadening its product range in this ... Extavia is the same as the MS treatment Betaferon

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...